Selinexor in Combination with Carboplatin and Pemetrexed in Patients with Advanced or Metastatic Solid Tumors: Results of an Open-Label, Single-Center, Multi-Arm Phase 1b Study

被引：1

作者：

Thein, Kyaw Z. ^{[1
,2
]}

Fu, Siqing ^{[1
]}

Janku, Filip ^{[1
]}

Tsimberidou, Apostolia M. ^{[1
]}

Piha-Paul, Sarina A. ^{[1
]}

Karp, Daniel D. ^{[1
]}

Shah, Jatin ^{[3
]}

Milton, Denai R. ^{[4
]}

Gong, Jing ^{[1
]}

Sulovic, Selma ^{[1
]}

McQuinn, Lacey ^{[1
]}

Stephen, Bettzy A. ^{[1
]}

Colen, Rivka R. ^{[5
]}

Carter, Brett W. ^{[6
]}

Meric-Bernstam, Funda ^{[1
]}

Naing, Aung ^{[1
]}

机构：

[1] Univ Texas MD Anderson Canc Ctr, Dept Invest Canc Therapeut, Houston, TX 77030 USA

[2] Oregon Hlth & Sci Univ, Div Hematol & Med Oncol, Knight Canc Inst, Portland, OR 97239 USA

[3] Karyopharm Therapeut, Newton, MA USA

[4] Univ Texas MD Anderson Canc Ctr, Dept Biostat, Houston, TX USA

[5] Univ Texas Md Anderson Canc Ctr, Dept Diagnost Radiol, Houston, TX USA

[6] Univ Texas MD Anderson Canc Ctr, Dept Thorac Imaging, Div Diagnost Imaging, Houston, TX USA

来源：

JOURNAL OF IMMUNOTHERAPY AND PRECISION ONCOLOGY | 2022年 / 5卷 / 01期

基金：

美国国家卫生研究院;

关键词：

selinexor; carboplatin; pemetrexed; metastatic solid tumors; selective inhibitor of nuclear export (SINE); NUCLEAR EXPORT; SELECTIVE INHIBITOR; II TRIAL; 1ST-IN-CLASS;

D O I：

10.36401/JIPO-21-20

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

引用

页码：10 / 12

页数：3

共 8 条

[1] Selinexor (KPT-330) demonstrates anti-tumor efficacy in preclinical models of triple-negative breast cancer [J].

Arango, Natalia Paez ;

Yuca, Erkan ;

Zhao, Ming ;

Evans, Kurt W. ;

Scott, Stephen ;

Kim, Charissa ;

Gonzalez-Angulo, Ana Maria ;

Janku, Filip ;

Ueno, Naoto T. ;

Tripathy, Debu ;

Akcakanat, Argun ;

Naing, Aung ;

Meric-Bernstam, Funda .

BREAST CANCER RESEARCH, 2017, 19

[2]

Baek Han Bit, 2018, Oncotarget, V9, P34567, DOI 10.18632/oncotarget.26179

[3] Phase IB Study of Selinexor, a First-in-Class Inhibitor of Nuclear Export, in Patients With Advanced Refractory Bone or Soft Tissue Sarcoma [J].

Gounder, Mrinal M. ;

Zer, Alona ;

Tap, William D. ;

Salah, Samer ;

Dickson, Mark A. ;

Gupta, Abha A. ;

Keohan, Mary Louise ;

Loong, Herbert H. ;

D'Angelo, Sandra P. ;

Baker, Stephanie ;

Condy, Mercedes ;

Nyquist-Schultz, Kjirsten ;

Tanner, Lanier ;

Erinjeri, Joseph P. ;

Jasmine, Francis H. ;

Friedlander, Sharon ;

Carlson, Robert ;

Unger, Thaddeus J. ;

Saint-Martin, Jean-Richard ;

Rashal, Tami ;

Ellis, Joel ;

Kauffman, Michael ;

Shacham, Sharon ;

Schwartz, Gary K. ;

Razak, Albiruni Ryan Abdul .

JOURNAL OF CLINICAL ONCOLOGY, 2016, 34 (26) :3166-+

[4]

Kashyap Trinayan, 2018, Oncotarget, V9, P30773, DOI 10.18632/oncotarget.25637

[5] First-in-Class, First-in-Human Phase I Study of Selinexor, a Selective Inhibitor of Nuclear Export, in Patients With Advanced Solid Tumors [J].

Razak, Albiruni R. Abdul ;

Mau-Soerensen, Morten ;

Gabrail, Nashat Y. ;

Gerecitano, John F. ;

Shields, Anthony F. ;

Unger, Thaddeus J. ;

Saint-Martin, Jean R. ;

Carlson, Robert ;

Landesman, Yosef ;

McCauley, Dilara ;

Rashal, Tami ;

Lassen, Ulrik ;

Kim, Richard ;

Stayner, Lee-Anne ;

Mirza, Mansoor R. ;

Kauffman, Michael ;

Shacham, Sharon ;

Mahipal, Amit .

JOURNAL OF CLINICAL ONCOLOGY, 2016, 34 (34) :4142-+

[6] A Phase II Trial of Selinexor (KPT-330) for Metastatic Triple-Negative Breast Cancer [J].

Shafique, Michael ;

IsmailKhan, Roohi ;

Extermann, Martine ;

Sullivan, Dan ;

Goodridge, Dawn ;

Boulware, David ;

Hogue, Deanna ;

Soliman, Hatem ;

Khong, Hung ;

Han, Hyo S. .

ONCOLOGIST, 2019, 24 (07) :887-+

[7] Phase 2 study of the Exportin 1 inhibitor selinexor in patients with recurrent gynecological malignancies [J].

Vergote, I. B. ;

Lund, B. ;

Peen, U. ;

Umajuridze, Z. ;

Mau-Sorensen, M. ;

Kranich, A. ;

Van Nieuwenhuysen, E. ;

Haslund, C. ;

Nottrup, T. ;

Han, S. N. ;

Concin, N. ;

Unger, T. J. ;

Chai, Y. ;

Au, N. ;

Rashal, T. ;

Joshi, A. ;

Crochiere, M. ;

Landesman, Y. ;

Shah, J. ;

Shacham, S. ;

Kauffman, M. ;

Mirza, M. R. .

GYNECOLOGIC ONCOLOGY, 2020, 156 (02) :308-314

[8] A Phase II Trial of Selinexor, an Oral Selective Inhibitor of Nuclear Export Compound, in Abiraterone- and/or Enzalutamide-Refractory Metastatic Castration-Resistant Prostate Cancer [J].

Wei, Xiao X. ;

Siegel, Adam P. ;

Aggarwal, Rahul ;

Lin, Amy M. ;

Friedlander, Terence W. ;

Fong, Lawrence ;

Kim, Won ;

Louttit, Mirela ;

Chang, Emily ;

Zhang, Li ;

Ryan, Charles J. .

ONCOLOGIST, 2018, 23 (06) :656-+

← 1 →